

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Xuanzhu Biopharmaceutical Co., Ltd.

軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

**VOLUNTARY ANNOUNCEMENT
SUCCESSFUL RENEWAL AND INCLUSION OF
THE INNOVATIVE DRUG ANJIUWEI IN THE 2025 NRDL**

The board of directors (the “**Board**”) of Xuanzhu Biopharmaceutical Co., Ltd. (the “**Company**” or “**Xuanzhu Biopharmaceutical**,” together with its subsidiaries as the “**Group**”) is pleased to announce that, following the simple medical insurance renewal with the National Healthcare Security Administration (the “**NHSA**”), the Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei), an innovative drug independently developed by the Company, will continue to be included in the new edition of the National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (2025) (the “**2025 NRDL**”) which is effective from January 1, 2026.

As the first and only proton pump inhibitor independently developed, Anjiuwei has been approved to be launched in the PRC in June 2023 for the treatment of duodenal ulcers and was first included in the National Reimbursement Drug List in December 2023. The successful renewal for Anjiuwei in the 2025 NRDL will be beneficial to stabilizing the market sales, and continue to benefit additional patient groups and enhance the penetration rate of the product in relevant indications, injecting momentum to the long-term growth of Anjiuwei.

About the Anaprazole Sodium Enteric-coated Tablets

The Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei) obtained market approval from the National Medical Products Administration in June 2023 for the treatment of patients with duodenal ulcers. Anaprazole Sodium features an innovative structural design, characterized by non-enzymatic plus multi-enzymatic metabolism, balanced double-channel excretion via the intestinal and renal pathways with only 3.5% metabolized by CYP2C19, making it unaffected by the gene polymorphism of CYP2C19. Compared with previous generations of proton pump inhibitors, Anaprazole Sodium is a proton pump inhibitor that is more suitable for Chinese people as it reduces risk of combination therapy, being a safer treatment option for patients on multiple medications and those with renal insufficiency. As a national Class 1 innovative drug, Anaprazole Sodium has filled the gap in the domestic independently developed proton pump inhibitors, offering patients in China treatment options that combine improved efficacy and safety profile. In addition to the approved indication for duodenal ulcers, the Phase III clinical trial of Anaprazole Sodium Enteric-coated Tablets for the treatment of reflux esophagitis commenced in full swing in July 2025.

This announcement is made by the Company on a voluntary basis to update the investors of the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun

Chairperson of the Board and executive Director

Hong Kong, December 8, 2025

As of the date of this announcement, the Board comprises (i) Ms. Xu Yanjun, Dr. Li Jia Kui and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; and (iii) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.